SCHEMBL4664347

SCHEMBL4664347

CN1CCC(CCOc2ccc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(F)cc5)cc4)ncn3)cc2F)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
ALOX15 P16050 2/20 0.40
CYP2C19 P33261 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
ABL1 P00519 6/20 0.37
BCR P11274 6/20 0.37
TRPA1 O75762 2/20 0.36
IKBKE Q14164 2/20 0.34
TBK1 Q9UHD2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665886 0.93 EGFR (0.37) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4665896 0.93 MEN1 (0.38) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4667466 0.91 ABL1 (0.36) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4665785 0.91 EGFR (0.35) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4664360 0.90 SYK (0.35) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4665787 0.87 ABL1 (0.41) ABL1BCRKDREGFRMET
SCHEMBL4665748 0.87 EGFR (0.42) ABL1BCRIKBKETBK1KDR
SCHEMBL4667481 0.86 PIK3R1 (0.42) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4666074 0.86 MEN1 (0.45) USP2ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL4666192 0.85 ABL1 (0.42) ABL1BCRBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 USP2 2576/4885ALDH1A1 2988/4885CYP1A2 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.